| 证券代码：300272 | 证券简称：开能健康 | 公告编号：2025-069 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 4、可转债停止转股日：2025 年 9 月 2 日 1、最后交易日：2025 年 8 月 27 日 2、2025 年 8 月 27 日为开能转债的最后一个交易日；当日可转债简称：Z 能转债；2025 年 8 月 27 日收市后开能转债将停止交易。 2、最后转股日：2025 年 9 月 1 日 2025 年 9 月 1 日为开能转债最后一个转股日，当日收市前，持有开能转债 的投资者仍可进行转股；2025 年 9 月 1 日收市后仍未转股的"开能转债"，将按 照 100.118 元/张的价格强制赎回，因目前"开能转债"二级市场价格与赎回价格 存在较大差异，特别提醒"开能转债"持有人注意在限期内转股，如果投资者未 及时转股，可能面临损失，敬请投资者注意投资风险。 截至 2025 年 8 月 26 日收市后，距离开能转债 ...

Core Viewpoint - The company, Kaineng Health, reported a revenue increase of 7.23% and a net profit increase of 22.99% for the first half of 2025, driven by increased production and cost dilution [1][2] Financial Performance - The company achieved an operating income of 889 million yuan and a net profit attributable to shareholders of 70.15 million yuan in the first half of 2025 [1] - The basic earnings per share were reported at 0.1241 yuan [1] - The comprehensive gross profit margin for the period was 41.12%, an increase of 0.62 percentage points compared to the same period last year [1] Product Structure - Revenue from terminal business and services was 545 million yuan, an increase of 9.90% year-on-year [1] - Revenue from intelligent manufacturing and core components was 331 million yuan, up 3.32% year-on-year [1] - Revenue from other ecological products and businesses was 12.83 million yuan, reflecting a growth of 1.65% year-on-year [1] Market Position - Kaineng Health has maintained a market share of over 35% in the Shanghai region for its whole-house water purification and softening machines for three consecutive years, ranking first [1] - The company has a comprehensive range of water treatment products, covering 8 major categories, 83 series, and over 1,700 specifications [1] Global Expansion Strategy - The company has successfully entered over 100 countries and regions with its water treatment products [2] - Kaineng Health has established a presence in the mature water treatment markets of North America through its subsidiary, Canature N.A. Inc. [2] - The company has a global network of distributors and partners, enhancing its overseas business development [2]

Core Viewpoint - The company announces the forced redemption of its convertible bonds, "Kaineng Convertible Bonds," at a price of 100.118 yuan per bond, effective September 1, 2025, due to the significant difference between the market price and the redemption price, urging bondholders to convert their bonds before the deadline to avoid potential losses [1][2][3]. Group 1: Convertible Bond Details - The company issued 2.5 million convertible bonds with a total value of 250 million yuan, with an initial conversion price set at 5.67 yuan per share [3]. - The conversion price has been adjusted multiple times due to dividend distributions, with the latest adjustment bringing it to 5.36 yuan per share [5][6]. - The conditional redemption clause was triggered when the stock price exceeded 130% of the conversion price for at least 15 trading days within a 30-day period [2][5]. Group 2: Redemption Process - The redemption price is confirmed at 100.118 yuan per bond, which includes accrued interest calculated based on the bond's face value and interest rate [7]. - The redemption will be executed for all bondholders registered by the close of trading on September 1, 2025, with the redemption funds expected to reach the bondholders' accounts by September 9, 2025 [7][8]. - The company emphasizes the importance of timely conversion and provides contact information for inquiries regarding the redemption process [8][9].

Group 1 - The company, Kaineng Health Technology Group Co., Ltd., has received approval for the issuance of convertible bonds, which was passed by the board meeting on October 28, 2022, and the third extraordinary general meeting of shareholders on November 15, 2022 [2] - The convertible bonds are set to be issued to unspecified objects, with the registration approval from the China Securities Regulatory Commission dated June 17, 2023 [2] - The bonds will be valid from July 26, 2023, until July 19, 2029, with interest payments scheduled [2] Group 2 - The company has proposed a mid-term dividend plan for 2025, distributing cash dividends of RMB 0.8 per 10 shares, totaling approximately RMB 47.56 million based on the latest total share capital of 594,532,905 shares [3][4] - The dividend payout is expected to account for 67-70% of the net profit attributable to shareholders for the period [3] - The proposed dividend plan aligns with the company's profit distribution policy and is designed to share operational results with shareholders without adversely affecting the company's liquidity [4]

Core Viewpoint - The company reported a revenue of 889 million RMB for the first half of 2025, reflecting a year-on-year growth of 7.23% [1] - The net profit attributable to shareholders reached 70.15 million RMB, marking a year-on-year increase of 22.99% [1] - The company proposed a cash dividend of 0.8 RMB per 10 shares to all shareholders [1] Financial Performance - Revenue for the first half of 2025: 889 million RMB, up 7.23% year-on-year [1] - Net profit attributable to shareholders: 70.15 million RMB, up 22.99% year-on-year [1] - Net profit excluding non-recurring gains and losses: 67.55 million RMB, up 24.82% year-on-year [1] - Basic earnings per share: 0.1241 RMB [1] Dividend Distribution - Proposed cash dividend: 0.8 RMB per 10 shares (including tax) [1]

开能健康科技集团股份有限公司 2025 年半年度报告全文 开能健康科技集团股份有限公司 2025 年半年度报告 公告编号：2025-066 2025 年 8 月 26 日 1 开能健康科技集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人瞿建国、主管会计工作负责人瞿亚明及会计机构负责人(会计 主管人员)刘文军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中所涉及的未来经营计划和未来目标等前瞻性陈述，不代表公司 的盈利预测或对投资者的实质性承诺。 公司在发展过程中，面临行业市场风险、关税及境外经营风险、并购带 来的财务风险、所投资标的公允价值变动可能影响公司经营业绩的风险以及 募投项目产生的风险等风险因素，上述风险及应对措施详见本报告第三节中 "十、公司面临的风险和应对措施"相关内容。敬请广大投资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以实施 ...

Group 1 - The core viewpoint of the article is that Kaien Health (SZ 300272) held its 25th meeting of the 6th board on August 22, 2025, to review the 2025 semi-annual report and other documents [1] - For the year 2024, the revenue composition of Kaien Health is entirely from the environmental equipment manufacturing and service industry, accounting for 100.0% [1] - As of the report, the market capitalization of Kaien Health is 4 billion yuan [1] Group 2 - The A-share market has seen trading volumes exceed 2 trillion yuan for eight consecutive days, indicating strong market activity [1] - Major brokerage firms are actively recruiting for the autumn season, with 25 job positions available, reflecting a demand for talent in the industry [1]

证券代码：300272 证券简称：开能健康 公告编号：2025-064 债券代码：123206 债券简称：开能转债 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、开能健康科技集团股份有限公司（下文简称"公司"）第六届监事会第二 十一次会议的会议通知于2025年8月12日以邮件方式发出。 2、本次监事会会议于2025年8月22日在上海市浦东新区川大路518号本公司 会议室，以现场结合通讯表决方式召开。 3、本次监事会会议应出席监事3名，实际出席监事3名。 5、本次监事会会议的召集、召开符合《公司法》等有关法律、法规和《公 司章程》的规定。 二、监事会会议决议情况 与会各位监事对本次监事会会议议案进行了认真审议，以现场结合通讯表决 方式进行了表决，且通过了以下决议： 1、会议以 3 票同意，0 票反对，0 票弃权，审议通过了《2025年半年度报 告》全文及其摘要； 经审核，监事会认为：董事会编制和审核公司2025年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2025年半年度经营的实际情 ...

证券代码：300272 证券简称：开能健康 公告编号：2025-063 债券代码：123206 债券简称：开能转债 与会各位董事对本次董事会会议议案进行了认真审议，以现场结合通讯方式 进行了表决，且通过了以下决议： 1、会议以 5 票同意，0 票反对，0 票弃权，审议通过了《2025年半年度报 告》及其摘要； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、开能健康科技集团股份有限公司（以下简称"公司"）第六届董事会第二 十五次会议的会议通知于2025年8月12日以邮件方式发出。 2、本次董事会会议于2025年8月22日在上海市浦东新区川大路518号公司会 议室以现场结合通讯的方式召开。 3、本次董事会会议应出席董事5名，实际出席董事5名。 4、本次董事会会议由董事长瞿建国先生主持，公司监事会成员及高级管理 人员列席了本次会议。 5、本次董事会会议的召集、召开符合《公司法》等有关法律、法规和《公 司章程》的规定。 二、董事会会议决议情况 具体内容详见在符合条件的媒体披露的《2025年半年度报告》《2025年半年 度报告摘要》，《20 ...

证券代码：300272 证券简称：开能健康 公告编号：2025-067 债券代码：123206 债券简称：开能转债 特别提示： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1、每10股分配比例：每10股派发现金红利人民币0.8元（含税），不送红股， 不以资本公积金转增股本。 4、本次中期分红方案已经公司第六届董事会第二十五次会议审议通过，根 据2024年年度股东会的授权，本次中期分红方案无需提交股东会审议。 一、审议程序 1、开能健康科技集团股份有限公司（以下简称"公司"）于2025年5月20 日召开2024年度股东大会，审议通过了《关于董事会提请股东大会授权2025年度 中期分红的议案》，为简化分红程序，公司股东会同意授权董事会根据股东大会 决议在符合利润分配的条件下制定具体的中期分红方案，且公司2025年中期结合 未分配利润与当期业绩进行分红，以当时总股本为基数，派发现金红利总金额不 超过当期净利润。 2、公司于2025年8月22日召开第六届董事会第二十五次会议，以同意5票、 第 1 页 共 3 页 反对0、弃权0票的表决结果审议通过了《关于<2025 ...